Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 92


Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts.

Williams S, Pettaway C, Song R, Papandreou C, Logothetis C, McConkey DJ.

Mol Cancer Ther. 2003 Sep;2(9):835-43.


The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim.

Nikrad M, Johnson T, Puthalalath H, Coultas L, Adams J, Kraft AS.

Mol Cancer Ther. 2005 Mar;4(3):443-9.


Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade.

Yerlikaya A, Erin N.

Int J Mol Med. 2008 Dec;22(6):817-23.


Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells.

Tsapakidis K, Vlachostergios PJ, Voutsadakis IA, Befani CD, Patrikidou A, Hatzidaki E, Daliani DD, Moutzouris G, Liakos P, Papandreou CN.

Int J Urol. 2012 Jun;19(6):565-74. doi: 10.1111/j.1442-2042.2012.02967.x. Epub 2012 Feb 10.


Stabilization and functional impairment of the tumor suppressor p53 by the human papillomavirus type 16 E7 oncoprotein.

Eichten A, Westfall M, Pietenpol JA, Münger K.

Virology. 2002 Mar 30;295(1):74-85.


The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status.

Pérez-Galán P, Roué G, Villamor N, Montserrat E, Campo E, Colomer D.

Blood. 2006 Jan 1;107(1):257-64. Epub 2005 Sep 15.


Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells.

Codony-Servat J, Tapia MA, Bosch M, Oliva C, Domingo-Domenech J, Mellado B, Rolfe M, Ross JS, Gascon P, Rovira A, Albanell J.

Mol Cancer Ther. 2006 Mar;5(3):665-75. Erratum in: Mol Cancer Ther. 2006 May;5(5):1383.


The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.

Strauss SJ, Higginbottom K, Jüliger S, Maharaj L, Allen P, Schenkein D, Lister TA, Joel SP.

Cancer Res. 2007 Mar 15;67(6):2783-90.


Sensitization of DNA damage-induced apoptosis by the proteasome inhibitor PS-341 is p53 dependent and involves target proteins 14-3-3sigma and survivin.

Vaziri SA, Hill J, Chikamori K, Grabowski DR, Takigawa N, Chawla-Sarkar M, Rybicki LR, Gudkov AV, Mekhail T, Bukowski RM, Ganapathi MK, Ganapathi R.

Mol Cancer Ther. 2005 Dec;4(12):1880-90.


JNK and AP-1 mediate apoptosis induced by bortezomib in HepG2 cells via FasL/caspase-8 and mitochondria-dependent pathways.

Lauricella M, Emanuele S, D'Anneo A, Calvaruso G, Vassallo B, Carlisi D, Portanova P, Vento R, Tesoriere G.

Apoptosis. 2006 Apr;11(4):607-25.


MDM2 mediated nuclear exclusion of p53 attenuates etoposide-induced apoptosis in neuroblastoma cells.

Rodriguez-Lopez AM, Xenaki D, Eden TO, Hickman JA, Chresta CM.

Mol Pharmacol. 2001 Jan;59(1):135-43.


Bortezomib inhibits docetaxel-induced apoptosis via a p21-dependent mechanism in human prostate cancer cells.

Canfield SE, Zhu K, Williams SA, McConkey DJ.

Mol Cancer Ther. 2006 Aug;5(8):2043-50.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk